Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430533 · ClinicalTrials.gov registry record · Phase 1
Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
NCT01430533 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 240 participants.
The verdict
NCT01430533, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dermal sensitization potential of azelaic acid pre-foam formulation.
Interventions
- DRUG Water
- DRUG azelaic acid pre foam formulation
- DRUG Vehicle pre foam formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430533
The ClinicalTrials.gov registry entry for NCT01430533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Water is the first listed.
NCT01430533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430533 about?
NCT01430533 is a clinical study titled "Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation". The purpose of this study is to determine the dermal sensitization potential of azelaic acid pre-foam formulation.
What is the current status of trial NCT01430533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2011-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01430533?
The interventions under investigation include: Water (DRUG), azelaic acid pre foam formulation (DRUG), Vehicle pre foam formulation (DRUG).
Who is sponsoring clinical trial NCT01430533?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.